First and foremost, Ivacaftor has initially been designed for improving the function of specific CFTR mutants in CF and is right now FDA-approved for the treatment of CF caused by a panel of CFTR mutations that altogether represent 5-10 percent of all CF cases60–64. Here, CFTR is linked to cystic fibrosis.